A number of firms have modified their ratings and price targets on shares of Crispr Therapeutics (NASDAQ: CRSP) recently:

  • 11/30/2019 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 11/26/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $104.00 price target on the stock.
  • 11/25/2019 – Crispr Therapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $80.00. They now have an “outperform” rating on the stock.
  • 11/20/2019 – Crispr Therapeutics had its price target raised by analysts at Canaccord Genuity from $72.00 to $80.00. They now have a “positive” rating on the stock.
  • 11/19/2019 – Crispr Therapeutics was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
  • 11/19/2019 – Crispr Therapeutics had its price target raised by analysts at Goldman Sachs Group Inc from $52.00 to $75.00. They now have a “neutral” rating on the stock.
  • 11/19/2019 – Crispr Therapeutics had its price target raised by analysts at Piper Jaffray Companies from $100.00 to $107.00. They now have a “buy” rating on the stock.
  • 11/19/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Wells Fargo & Co.
  • 11/19/2019 – Crispr Therapeutics had its price target raised by analysts at Roth Capital from $65.00 to $100.00.
  • 11/18/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock.
  • 11/15/2019 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/12/2019 – Crispr Therapeutics was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $65.00 price target on the stock.
  • 11/1/2019 – Crispr Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 10/31/2019 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/28/2019 – Crispr Therapeutics was upgraded by analysts at TheStreet from a “d” rating to a “c” rating.
  • 10/25/2019 – Crispr Therapeutics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/21/2019 – Crispr Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 10/21/2019 – Crispr Therapeutics was given a new $72.50 price target on by analysts at Chardan Capital. They now have a “buy” rating on the stock.
  • 10/15/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock.
  • 10/11/2019 – Crispr Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Crispr Therapeutics stock traded down $1.39 on Thursday, hitting $70.71. The company’s stock had a trading volume of 1,076,777 shares, compared to its average volume of 703,067. The firm has a market cap of $3.95 billion, a P/E ratio of -20.56 and a beta of 3.30. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average price of $53.47 and a 200-day moving average price of $47.06. Crispr Therapeutics AG has a one year low of $22.22 and a one year high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Analysts anticipate that Crispr Therapeutics AG will post 0.65 EPS for the current year.

In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Benjamin Edwards Inc. increased its holdings in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after purchasing an additional 268 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Crispr Therapeutics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after purchasing an additional 343 shares during the last quarter. Traynor Capital Management Inc. increased its stake in shares of Crispr Therapeutics by 5.8% in the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after buying an additional 375 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Crispr Therapeutics by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after buying an additional 386 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Crispr Therapeutics by 7.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after buying an additional 467 shares during the last quarter. 49.81% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Read More: Current Ratio



Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.



Source link